N/A N=230 70 vs 110 Degree Side-cut Angles in Femtosecond LASIK
Operative Incision
Primary: Uncorrected Visual Acuity at One Year — -0.082; -0.094 logMAR Visual Acuity
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=900 A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy
Diabetic Retinopathy
Primary: Sensitivity Corrected for Enrichment — 87.2 percentage of true positives
Phase 3 N=1,129 Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial
Smallpox
Primary: Vaccinia-Specific Neutralizing Antibodies Measured by Plaque Reduction Neutralization Test (PRNT) — 252.7; 269.9; 242.0 Titer
Phase 4 N=270 Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)
Multiple Sclerosis
Primary: Change From Baseline Period (Period Screening to Baseline) in Counts of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions at Period 1 (Month 1-6)…
N/A N=25 Intramuscular Heating Rates of a Chattanooga Intelect XT Therapeutic Ultrasound
Ultrasound Therapy; Complications
Primary: Heating Rate at 1 cm Depth — 6.49 degrees Celcius
N/A N=214 Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort
Encephalitis · Meningitis
Primary: Total Number of Cases With at Least One Provider Response — 98; 58 cases
Phase 3 N=41 Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
CCND1 Gene Amplification · CCND2 Gene Amplification · CCND3 Gene Amplification
Primary: Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial) — 6 percentage of participants
N/A N=27 How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype (ALP)?
Non-alcoholic Fatty Liver Disease (NAFLD)
Primary: Production Rate of VLDL-1 Triacylglycerol (TAG) — 20.9; 18.9; 16.6; 12.4 grams/day — p=<0.05
N/A N=40 An Evaluation of Low Level Laser Light Therapy for Autistic Disorder
Autistic Disorder
Primary: Mean Change From Baseline to Study Endpoint in the Aberrant Behavior Checklist (ABC) Irritability & Agitation Subscale Score. — -14.81; 0.37 score on a scale
Phase 3 N=335 Test for Pre Operative Skin Preparations
Topical Antisepsis
Primary: log10 Reductions From Baseline for Each Test Parameter in CFU (Colony Forming Unit)/cm2 on Inguinal and Abdominal Sites — 3.51; 3.44; 3.15; 0.92 Average log10 reductions…
N/A N=44 Programs To Support You During Chemotherapy
Depression · Fatigue · Stage IIA Colorectal Cancer
Primary: Fatigue Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) — 53.1; 56.8; 53.0; 57.2 score on a scale
N/A N=28 Feasibility and Effectiveness of Micronutrients as Palliative Care Therapy in Patients With Congestive Heart Failure
Congestive Heart Failure · Ischemic Cardiomyopathy
Primary: Change in Left Ventricular Ejection Fraction by Echocardiogram — 1.1 Percent — p=0.64
Phase 3 N=18 Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism
Parathyroid Carcinoma · Primary Hyperparathyroidism
Primary: The Number and Percentage of Patients Who Achived a Serum Corrected Ca Concentration of Under 10.3 mg/dL for at Least 2weeks During Titration Phase. — 14 Participants
Phase 1 N=56 Dose-finding Pharmacokinetic Study in Healthy Males
Healthy Volunteers
Primary: Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24) — 4300; 5423; 7439; 9046 h*ng/ml
Phase 3 N=34 Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
FGFR1 Gene Amplification · FGFR1 Gene Mutation · FGFR2 Gene Amplification
Primary: Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial) — 7 percentage of participants